February 18, 2022
Axicabtagene ciloleucel is an autologous anti-CD19 CAR T cell therapy indicated for the treatment of Relapsed/Refractory (R/R) large B-cell lymphoma and follicular lymphoma (FL), both after […]
April 27, 2021
The potent KITD816V inhibitor induced durable responses that deepened over time in patients with this disease, regardless of prior therapy or the presented subtype A provisional and pre-specified analysis of PATHFINDER (NCT03580655), a phase II, open-label and […]
April 23, 2021
Gamma9 Delta2 (γ9δ2) T cells function at the crossroads of innate and adaptive immunity, with important roles in immune responses against pathogens and carcinogenesis, making them an attractive […]
April 22, 2021
Rituximab-based therapies are standard in the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (iLNH). Copanlisib, an intravenous PI3K inhibitor, has demonstrated efficacy and safety as monotherapy […]
July 17, 2020
Overall survival and event-free survival were higher in the group with total body irradiation and treatment-related mortality was higher in the group with chemotherapy At the […]
April 20, 2020
Efficacy was demonstrated in a study involving 153 patients The U.S. Food and Drug Administration (FDA) has approved luspatercept-aamt (REBLOZYL®) for the treatment of anemia in […]
April 16, 2020
Last week, The Lancet Haematology magazine published a strategic plan, developed by a Chinese group, for the management of outbreaks of COVID-19 in pediatric hematology and […]
January 10, 2019
Tagraxofusp-erzs™ (Elzonris) infusion was granted US Food and Drug Administration (FDA) approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to news releases […]